Trending Stock News

Reata Pharmaceuticals, Inc. (RETA) Reaches $32.01 After 6.00% Up Move; Stifel Financial Has Raised Berkshire Hills Bancorp (BHLB) Stake By $522,792

Berkshire Hills Bancorp, Inc. (NYSE:BHLB) Logo

The stock of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is a huge mover today! The stock increased 4.44% or $1.36 during the last trading session, reaching $32.01. About 144,009 shares traded. Reata Pharmaceuticals, Inc. (NASDAQ:RETA) has declined 19.56% since May 16, 2017 and is downtrending. It has underperformed by 31.11% the S&P500.The move comes after 8 months positive chart setup for the $837.53M company. It was reported on May, 16 by Barchart.com. We have $33.93 PT which if reached, will make NASDAQ:RETA worth $50.25 million more.

Stifel Financial Corp increased Berkshire Hills Bancorp Inc (BHLB) stake by 17.53% reported in 2017Q4 SEC filing. Stifel Financial Corp acquired 14,522 shares as Berkshire Hills Bancorp Inc (BHLB)’s stock rose 0.94%. The Stifel Financial Corp holds 97,377 shares with $3.56M value, up from 82,855 last quarter. Berkshire Hills Bancorp Inc now has $1.74B valuation. The stock increased 0.33% or $0.125 during the last trading session, reaching $38.275. About 117,452 shares traded. Berkshire Hills Bancorp, Inc. (NYSE:BHLB) has risen 6.95% since May 16, 2017 and is uptrending. It has underperformed by 4.60% the S&P500.

More important recent Reata Pharmaceuticals, Inc. (NASDAQ:RETA) news were published by: Seekingalpha.com which released: “Reata Pharmaceuticals’ (RETA) CEO Warren Huff on Q1 2018 Results – Earnings Call Transcript” on May 13, 2018, also Nasdaq.com published article titled: “Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development Programs”, Nasdaq.com published: “Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s …” on April 24, 2018. More interesting news about Reata Pharmaceuticals, Inc. (NASDAQ:RETA) was released by: Investingnews.com and their article: “Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone” with publication date: April 25, 2018.

Analysts await Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to report earnings on August, 13. They expect $-0.75 EPS, down 44.23% or $0.23 from last year’s $-0.52 per share. After $0.15 actual EPS reported by Reata Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -600.00% negative EPS growth.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company has market cap of $837.53 million. The Company’s lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of FriedreichÂ’s ataxia, mitochondrial myopathies, and metastatic melanoma. It currently has negative earnings. The firm was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

Stifel Financial Corp decreased Scana Corp New (NYSE:SCG) stake by 89,224 shares to 29,536 valued at $1.17M in 2017Q4. It also reduced Tesla Inc (NASDAQ:TSLA) stake by 2,334 shares and now owns 17,212 shares. Synchrony Finl (NYSE:SYF) was reduced too.

Since December 15, 2017, it had 6 insider purchases, and 0 sales for $557,768 activity. Sheehan Patrick J also bought $331,711 worth of Berkshire Hills Bancorp, Inc. (NYSE:BHLB) on Monday, February 5. 3,000 shares were bought by RYAN WILLIAM J, worth $113,608 on Friday, December 15. Murphy Richard L. also bought $36,999 worth of Berkshire Hills Bancorp, Inc. (NYSE:BHLB) shares. Bossidy Paul T had bought 500 shares worth $19,125 on Friday, April 27.

Investors sentiment decreased to 1.24 in Q4 2017. Its down 0.34, from 1.58 in 2017Q3. It turned negative, as 14 investors sold BHLB shares while 56 reduced holdings. 29 funds opened positions while 58 raised stakes. 30.63 million shares or 3.99% more from 29.46 million shares in 2017Q3 were reported. Boston Advisors Limited Company owns 152,370 shares. C M Bidwell & Assoc Limited stated it has 0.07% of its portfolio in Berkshire Hills Bancorp, Inc. (NYSE:BHLB). Hbk Invs Limited Partnership stated it has 0.01% of its portfolio in Berkshire Hills Bancorp, Inc. (NYSE:BHLB). Wells Fargo Mn has invested 0% in Berkshire Hills Bancorp, Inc. (NYSE:BHLB). Guggenheim Ltd Liability Com has 51,914 shares. Shell Asset Mngmt Com holds 26,316 shares or 0.02% of its portfolio. Fj Cap Ltd Liability Corporation accumulated 80,000 shares or 0.37% of the stock. Genesee Valley Trust, New York-based fund reported 5,649 shares. Royal Bank Of Canada owns 3,604 shares for 0% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 4,014 shares or 0% of all its holdings. Farmers Merchants Investments Inc, Nebraska-based fund reported 228 shares. Great Lakes Advsr Lc accumulated 183,481 shares. Century Cos invested in 45,831 shares or 0% of the stock. Aqr Management Ltd Liability Co, a Connecticut-based fund reported 88,001 shares. Moreover, Jpmorgan Chase & has 0% invested in Berkshire Hills Bancorp, Inc. (NYSE:BHLB).

Berkshire Hills Bancorp, Inc. (NYSE:BHLB) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *